Oncology News | pharmaphorum

News

AACR: Affimed builds case for natural killer cell therapy

Affimed says new data from a phase 1/2 trial of its natural killer (NK) cell engager therapy AFM13 provide further evidence of its efficacy in treating CD30+ Hodgkin and non-Hodgkin lymphom

News

AACR: BioNTech finds value in CAR-T/mRNA vaccine combo

Adding an mRNA vaccine to CAR-T cell therapy could be the key to unlocking activity in solid tumours, according to German biotech BioNTech

News

Jazz adds first immuno-oncology drug via $1.3bn Werewolf dea...

Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate.

News

EMA starts review of Novartis' latecomer PD-1 drug tislelizu...

The EU regulator has started a review of Novartis' PD-1 inhibitor tislelizumab – licensed from Chinese biotech BeiGene – for oesophageal and lung cancers, ahead of an FDA decision on the dr

News

Gilead beats BMS to FDA okay for early lymphoma CAR-T therap...

Gilead Sciences' Kite Pharma has become the first drugmaker to get FDA approval to use a CAR-T therapy after just one earlier systemic therapy, moving the approach up the treatment pathway.

News

Roche hit by failure of TIGIT drug tiragolumab in lung cance...

Roche has suffered a setback with its much-anticipated pairing of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq in small cell lung cancer (SCLC), in a blow to its ambitions

AACR: Affimed builds case for natural killer cell therapy

AACR: BioNTech finds value in CAR-T/mRNA vaccine combo

Jazz adds first immuno-oncology drug via $1.3bn Werewolf dea...

EMA starts review of Novartis' latecomer PD-1 drug tislelizu...

Gilead beats BMS to FDA okay for early lymphoma CAR-T therap...

Roche hit by failure of TIGIT drug tiragolumab in lung cance...

Argenx pens $2.2bn deal to buy autoimmune biotech Forte

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks